Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Multiple Sclerosis

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 86 articles:
HTML format



Single Articles


    January 2021
  1. JOHNSON DK, Reynolds KM, Poole BD, Montierth MD, et al
    Contribution of viral infection to risk for cancer in systemic lupus erythematosus and multiple sclerosis.
    PLoS One. 2021;16:e0243150.
    PubMed     Abstract available


  2. THALER C, Kyselyova AA, Faizy TD, Nawka MT, et al
    Heterogeneity of multiple sclerosis lesions in fast diffusional kurtosis imaging.
    PLoS One. 2021;16:e0245844.
    PubMed     Abstract available


  3. WILSKI M, Brola W, Luniewska M, Tomczak M, et al
    The perceived impact of multiple sclerosis and self-management: The mediating role of coping strategies.
    PLoS One. 2021;16:e0248135.
    PubMed     Abstract available


  4. GOODIN DS, Khankhanian P, Gourraud PA, Vince N, et al
    The nature of genetic and environmental susceptibility to multiple sclerosis.
    PLoS One. 2021;16:e0246157.
    PubMed     Abstract available


  5. PRIDHAM G, Hossain S, Rawji KS, Zhang Y, et al
    A metric learning method for estimating myelin content based on T2-weighted MRI from a de- and re-myelination model of multiple sclerosis.
    PLoS One. 2021;16:e0249460.
    PubMed     Abstract available


  6. GOUJON A, Mirafzal S, Zuber K, Deschamps R, et al
    3D-Fast Gray Matter Acquisition with Phase Sensitive Inversion Recovery Magnetic Resonance Imaging at 3 Tesla: Application for detection of spinal cord lesions in patients with multiple sclerosis.
    PLoS One. 2021;16:e0247813.
    PubMed     Abstract available


  7. CHOI S, Spini M, Hua J, Harrison DM, et al
    Blood-brain barrier breakdown in non-enhancing multiple sclerosis lesions detected by 7-Tesla MP2RAGE DeltaT1 mapping.
    PLoS One. 2021;16:e0249973.
    PubMed     Abstract available


  8. GOLAN D, Sagiv S, Glass-Marmor L, Miller A, et al
    Mobile-phone-based e-diary derived patient reported outcomes: Association with clinical disease activity, psychological status and quality of life of patients with multiple sclerosis.
    PLoS One. 2021;16:e0250647.
    PubMed     Abstract available


  9. KLISTORNER S, Barnett MH, Wasserthal J, Yiannikas C, et al
    Differentiating axonal loss and demyelination in chronic MS lesions: A novel approach using single streamline diffusivity analysis.
    PLoS One. 2021;16:e0244766.
    PubMed     Abstract available


  10. PAPP V, Buron MD, Siersma V, Rasmussen PV, et al
    Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
    PLoS One. 2021;16:e0250820.
    PubMed     Abstract available


  11. KOENIG KA, Beall EB, Sakaie KE, Ontaneda D, et al
    Evaluation of a connectivity-based imaging metric that reflects functional decline in Multiple Sclerosis.
    PLoS One. 2021;16:e0251338.
    PubMed     Abstract available


  12. CARTER B, Hayes C, Smith A, Pennington A, et al
    A single patient reported outcome measure for acquired brain injury, multiple sclerosis & Parkinson's disease.
    PLoS One. 2021;16:e0251484.
    PubMed     Abstract available


  13. ROGACZEWSKA M, Michalak S, Stopa M
    Macular vessel density differs in multiple sclerosis and neuromyelitis optica spectrum disorder: An optical coherence tomography angiography study.
    PLoS One. 2021;16:e0253417.
    PubMed     Abstract available


  14. BSTEH G, Assar H, Hegen H, Heschl B, et al
    COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry.
    PLoS One. 2021;16:e0255316.
    PubMed     Abstract available


  15. GOODIN DS, Oksenberg JR, Douillard V, Gourraud PA, et al
    Genetic susceptibility to multiple sclerosis in African Americans.
    PLoS One. 2021;16:e0254945.
    PubMed     Abstract available


  16. SERAJI M, Mohebbi M, Safari A, Krekelberg B, et al
    Multiple sclerosis reduces synchrony of the magnocellular pathway.
    PLoS One. 2021;16:e0255324.
    PubMed     Abstract available


  17. GAJ S, Ontaneda D, Nakamura K
    Automatic segmentation of gadolinium-enhancing lesions in multiple sclerosis using deep learning from clinical MRI.
    PLoS One. 2021;16:e0255939.
    PubMed     Abstract available


  18. NG KEE KWONG KC, Mollison D, Meijboom R, York EN, et al
    The prevalence of paramagnetic rim lesions in multiple sclerosis: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0256845.
    PubMed     Abstract available


  19. SANTISTEBAN L, Teremetz M, Irazusta J, Lindberg PG, et al
    Outcome measures used in trials on gait rehabilitation in multiple sclerosis: A systematic literature review.
    PLoS One. 2021;16:e0257809.
    PubMed     Abstract available


  20. MOCCIA M, Affinito G, Capacchione A, Lanzillo R, et al
    Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: Merging the real-life to routinely collected healthcare data.
    PLoS One. 2021;16:e0258017.
    PubMed     Abstract available


  21. MECA-LALLANA JE, Oreja-Guevara C, Munoz D, Olascoaga J, et al
    Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.
    PLoS One. 2021;16:e0258437.
    PubMed     Abstract available


  22. STERNBACH S, West N, Singhal NK, Clements R, et al
    The BHMT-betaine methylation pathway epigenetically modulates oligodendrocyte maturation.
    PLoS One. 2021;16:e0250486.
    PubMed     Abstract available


  23. ROZYCKA J
    How I see is how I feel. Identification of illness perception schema and its association with adaptation outcomes in multiple sclerosis - a 5-year prospective study.
    PLoS One. 2021;16:e0258740.
    PubMed     Abstract available


  24. ALKETBI A, Basit S, Hamza N, Walton LM, et al
    The added value of cognition-targeted exercise versus symptom-targeted exercise for multiple sclerosis fatigue: A randomized controlled pilot trial.
    PLoS One. 2021;16:e0258752.
    PubMed     Abstract available


  25. KRUGER K, Fricke LM, Dilger EM, Thiele A, et al
    How is and how should healthcare for people with multiple sclerosis in Germany be designed?-The rationale and protocol for the mixed-methods study Multiple Sclerosis-Patient-Oriented Care in Lower Saxony (MS-PoV).
    PLoS One. 2021;16:e0259855.
    PubMed     Abstract available


  26. VERES G, Vas NF, Lyngby Lassen M, Beresova M, et al
    Effect of grey-level discretization on texture feature on different weighted MRI images of diverse disease groups.
    PLoS One. 2021;16:e0253419.
    PubMed     Abstract available


  27. MARRIE RA, Walld R, Bolton JM, Sareen J, et al
    Effect of comorbid mood and anxiety disorders on breast and cervical cancer screening in immune-mediated inflammatory disease.
    PLoS One. 2021;16:e0249809.
    PubMed     Abstract available


  28. MIMPEN M, Rolf L, Poelmans G, van den Ouweland J, et al
    Vitamin D related genetic polymorphisms affect serological response to high-dose vitamin D supplementation in multiple sclerosis.
    PLoS One. 2021;16:e0261097.
    PubMed     Abstract available


  29. ZANGENEH Z, Abdi-Ali A, Khamooshian K, Alvandi A, et al
    Bacterial variation in the oral microbiota in multiple sclerosis patients.
    PLoS One. 2021;16:e0260384.
    PubMed     Abstract available


    January 2020
  30. HJORTH M, Dandu N, Mellergard J
    Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets.
    PLoS One. 2020;15:e0228380.
    PubMed     Abstract available


  31. GIOVANNETTI AM, Pietrolongo E, Borreani C, Giordano A, et al
    Conversion to secondary progressive multiple sclerosis: Multistakeholder experiences and needs in Italy.
    PLoS One. 2020;15:e0228587.
    PubMed     Abstract available


  32. GRANER M, Pointon T, Manton S, Green M, et al
    Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides.
    PLoS One. 2020;15:e0228883.
    PubMed     Abstract available


  33. SELGRADE BP, Meyer D, Sosnoff JJ, Franz JR, et al
    Can optical flow perturbations detect walking balance impairment in people with multiple sclerosis?
    PLoS One. 2020;15:e0230202.
    PubMed     Abstract available


  34. SECCIA R, Gammelli D, Dominici F, Romano S, et al
    Considering patient clinical history impacts performance of machine learning models in predicting course of multiple sclerosis.
    PLoS One. 2020;15:e0230219.
    PubMed     Abstract available


  35. AKAISHI T, Takahashi T, Fujihara K, Misu T, et al
    Number of MRI T1-hypointensity corrected by T2/FLAIR lesion volume indicates clinical severity in patients with multiple sclerosis.
    PLoS One. 2020;15:e0231225.
    PubMed     Abstract available


  36. BARRERO F, Mallada-Frechin J, Martinez-Gines ML, Marzo ME, et al
    Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study.
    PLoS One. 2020;15:e0230846.
    PubMed     Abstract available


  37. GIOVANNETTI AM, Quintas R, Tramacere I, Giordano A, et al
    A resilience group training program for people with multiple sclerosis: Results of a pilot single-blind randomized controlled trial and nested qualitative study.
    PLoS One. 2020;15:e0231380.
    PubMed     Abstract available


  38. SILVA T, Fragoso YD, Destro Rodrigues MFS, Gomes AO, et al
    Effects of photobiomodulation on interleukin-10 and nitrites in individuals with relapsing-remitting multiple sclerosis - Randomized clinical trial.
    PLoS One. 2020;15:e0230551.
    PubMed     Abstract available


  39. HASHEMI R, Hosseini-Asl SS, Arefhosseini SR, Morshedi M, et al
    The impact of vitamin D3 intake on inflammatory markers in multiple sclerosis patients and their first-degree relatives.
    PLoS One. 2020;15:e0231145.
    PubMed     Abstract available


  40. MASUDA H, Mori M, Uzawa A, Uchida T, et al
    Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis.
    PLoS One. 2020;15:e0224419.
    PubMed     Abstract available


  41. PARRAVICINI C, Lecca D, Marangon D, Coppolino GT, et al
    Development of the first in vivo GPR17 ligand through an iterative drug discovery pipeline: A novel disease-modifying strategy for multiple sclerosis.
    PLoS One. 2020;15:e0231483.
    PubMed     Abstract available


  42. GOITIA B, Bruno D, Abrevaya S, Sedeno L, et al
    The relationship between executive functions and fluid intelligence in multiple sclerosis.
    PLoS One. 2020;15:e0231868.
    PubMed     Abstract available


  43. SAURI-SUAREZ S, Quinones-Aguilar S, Contreras-Marin A, Ramiro-Guerrero EO, et al
    Adherence to self-administering interferon-beta1a using RebiSmart(R) device in Mexican patients with relapsing multiple sclerosis.
    PLoS One. 2020;15:e0230959.
    PubMed     Abstract available


  44. OHLMEIER C, Gothe H, Haas J, Osowski U, et al
    Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data.
    PLoS One. 2020;15:e0231846.
    PubMed     Abstract available


  45. GOUGH N, Brkan L, Subramaniam P, Chiuccariello L, et al
    Feasibility of remotely supervised transcranial direct current stimulation and cognitive remediation: A systematic review.
    PLoS One. 2020;15:e0223029.
    PubMed     Abstract available


  46. GOLDMAN MD, Dwyer L, Coleman R, Sohn MW, et al
    Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients.
    PLoS One. 2020;15:e0228617.
    PubMed     Abstract available


  47. KUSNIEROVA P, Zeman D, Hradilek P, Zapletalova O, et al
    Determination of chitinase 3-like 1 in cerebrospinal fluid in multiple sclerosis and other neurological diseases.
    PLoS One. 2020;15:e0233519.
    PubMed     Abstract available


  48. BROWN FS, Glasmacher SA, Kearns PKA, MacDougall N, et al
    Systematic review of prediction models in relapsing remitting multiple sclerosis.
    PLoS One. 2020;15:e0233575.
    PubMed     Abstract available


  49. BAUER A, Lechner I, Auer M, Berger T, et al
    Influence of physical activity on serum vitamin D levels in people with multiple sclerosis.
    PLoS One. 2020;15:e0234333.
    PubMed     Abstract available


  50. LUCCHETTA RC, Leonart LP, Goncalves MVM, Becker J, et al
    Reliability in long-term clinical studies of disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review.
    PLoS One. 2020;15:e0231722.
    PubMed     Abstract available


  51. JULIAN GS, Rosim RP, Carneseca EC, Rigolon J, et al
    Annualized hospitalization rate with natalizumab vs fingolimod in second-line treatment for RRMS in the public healthcare system in Brazil: A claim database approach.
    PLoS One. 2020;15:e0229768.
    PubMed     Abstract available


  52. CHERAGHMAKANI H, Baghbanian SM, HabibiSaravi R, Azar A, et al
    Age and sex-adjusted incidence and yearly prevalence of multiple sclerosis (MS) in Mazandaran province, Iran: An 11-years study.
    PLoS One. 2020;15:e0235562.
    PubMed     Abstract available


  53. ROTSTEIN DL, Marrie RA, Tu K, Schultz SE, et al
    Health service utilization in immigrants with multiple sclerosis.
    PLoS One. 2020;15:e0234876.
    PubMed     Abstract available


  54. NINOU I, Sevastou I, Magkrioti C, Kaffe E, et al
    Genetic deletion of Autotaxin from CD11b+ cells decreases the severity of experimental autoimmune encephalomyelitis.
    PLoS One. 2020;15:e0226050.
    PubMed     Abstract available


  55. FARCI R, Carta A, Cocco E, Frau J, et al
    Optical coherence tomography angiography in multiple sclerosis: A cross-sectional study.
    PLoS One. 2020;15:e0236090.
    PubMed     Abstract available


  56. ILJICSOV A, Milanovich D, Ajtay A, Oberfrank F, et al
    Incidence and prevalence of multiple sclerosis in Hungary based on record linkage of nationwide multiple healthcare administrative data.
    PLoS One. 2020;15:e0236432.
    PubMed     Abstract available


  57. KEMMERER CL, Pernpeintner V, Ruschil C, Abdelhak A, et al
    Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-beta, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
    PLoS One. 2020;15:e0235449.
    PubMed     Abstract available


  58. CAVERZASI E, Cordano C, Zhu AH, Zhao C, et al
    Imaging correlates of visual function in multiple sclerosis.
    PLoS One. 2020;15:e0235615.
    PubMed     Abstract available


  59. PAMPHLETT R, Mak R, Lee J, Buckland ME, et al
    Concentrations of toxic metals and essential trace elements vary among individual neurons in the human locus ceruleus.
    PLoS One. 2020;15:e0233300.
    PubMed     Abstract available


  60. SINHA S, Renavikar PS, Crawford MP, Steward-Tharp SM, et al
    Altered expression of SIRPgamma on the T-cells of relapsing remitting multiple sclerosis and type 1 diabetes patients could potentiate effector responses from T-cells.
    PLoS One. 2020;15:e0238070.
    PubMed     Abstract available


  61. MORALES PANTOJA IE, Smith MD, Rajbhandari L, Cheng L, et al
    iPSCs from people with MS can differentiate into oligodendrocytes in a homeostatic but not an inflammatory milieu.
    PLoS One. 2020;15:e0233980.
    PubMed     Abstract available


  62. SOUZA KM, Diniz IM, Lemos LLP, Junior NGR, et al
    Effectiveness of first-line treatment for relapsing-remitting multiple sclerosis in Brazil: A 16-year non-concurrent cohort study.
    PLoS One. 2020;15:e0238476.
    PubMed     Abstract available


  63. ALNAJASHI H, Jabbad R
    Behavioral practices of patients with multiple sclerosis during Covid-19 pandemic.
    PLoS One. 2020;15:e0241103.
    PubMed     Abstract available


  64. COTTRELL L, Economos G, Evans C, Silber E, et al
    A realist review of advance care planning for people with multiple sclerosis and their families.
    PLoS One. 2020;15:e0240815.
    PubMed     Abstract available


  65. MELNIKOV M, Sharanova S, Sviridova A, Rogovskii V, et al
    The influence of glatiramer acetate on Th17-immune response in multiple sclerosis.
    PLoS One. 2020;15:e0240305.
    PubMed     Abstract available


  66. PERLEJEWSKI K, Bukowska-Osko I, Rydzanicz M, Dzieciatkowski T, et al
    Search for viral agents in cerebrospinal fluid in patients with multiple sclerosis using real-time PCR and metagenomics.
    PLoS One. 2020;15:e0240601.
    PubMed     Abstract available


  67. ZHANG X, Gao B, Xu B
    No association between the vitamin D-binding protein (DBP) gene polymorphisms (rs7041 and rs4588) and multiple sclerosis and type 1 diabetes mellitus: A meta-analysis.
    PLoS One. 2020;15:e0242256.
    PubMed     Abstract available


  68. BEREK K, Hegen H, Auer M, Zinganell A, et al
    Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi.
    PLoS One. 2020;15:e0239453.
    PubMed     Abstract available


  69. NIKOLIC B, Ivancevic N, Zaletel I, Rovcanin B, et al
    Characteristics of pediatric multiple sclerosis: A tertiary referral center study.
    PLoS One. 2020;15:e0243031.
    PubMed     Abstract available


  70. CORDON B, Vilades E, Orduna E, Satue M, et al
    Angiography with optical coherence tomography as a biomarker in multiple sclerosis.
    PLoS One. 2020;15:e0243236.
    PubMed     Abstract available


  71. VICKARYOUS N, Jitlal M, Jacobs BM, Middleton R, et al
    Remote testing of vitamin D levels across the UK MS population-A case control study.
    PLoS One. 2020;15:e0241459.
    PubMed     Abstract available


    January 2019
  72. JONGEN PJ, van Mastrigt GA, Heerings M, Visser LH, et al
    Effect of an intensive 3-day social cognitive treatment (can do treatment) on control self-efficacy in patients with relapsing remitting multiple sclerosis and low disability: A single-centre randomized controlled trial.
    PLoS One. 2019;14:e0223482.
    PubMed     Abstract available


  73. AMATO MP, Prestipino E, Bellinvia A, Niccolai C, et al
    Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors.
    PLoS One. 2019;14:e0222929.
    PubMed     Abstract available


  74. WORMSBECKER AE, Johnson C, Bourns L, Harris T, et al
    Demonstration of background rates of three conditions of interest for vaccine safety surveillance.
    PLoS One. 2019;14:e0210833.
    PubMed     Abstract available


  75. AMATO MP, Prestipino E, Bellinvia A, Niccolai C, et al
    Correction: Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors.
    PLoS One. 2019;14:e0225494.
    PubMed     Abstract available


  76. BOQUETE L, Lopez-Guillen E, Vilades E, Miguel-Jimenez JM, et al
    Diagnostic ability of multifocal electroretinogram in early multiple sclerosis using a new signal analysis method.
    PLoS One. 2019;14:e0224500.
    PubMed     Abstract available


  77. CORTINI A, Bembich S, Marson L, Cocco E, et al
    Identification of novel non-myelin biomarkers in multiple sclerosis using an improved phage-display approach.
    PLoS One. 2019;14:e0226162.
    PubMed     Abstract available


  78. BURKILL S, Vattulainen P, Geissbuehler Y, Sabido Espin M, et al
    The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis.
    PLoS One. 2019;14:e0227120.
    PubMed     Abstract available


  79. EHLING R, Amprosi M, Kremmel B, Bsteh G, et al
    Second language learning induces grey matter volume increase in people with multiple sclerosis.
    PLoS One. 2019;14:e0226525.
    PubMed     Abstract available


  80. POSTIGO-ALONSO B, Galvao-Carmona A, Conde-Gavilan C, Jover A, et al
    The effect of prioritization over cognitive-motor interference in people with relapsing-remitting multiple sclerosis and healthy controls.
    PLoS One. 2019;14:e0226775.
    PubMed     Abstract available


  81. MELIS M, Littera R, Cocco E, Frau J, et al
    Entropy of human leukocyte antigen and killer-cell immunoglobulin-like receptor systems in immune-mediated disorders: A pilot study on multiple sclerosis.
    PLoS One. 2019;14:e0226615.
    PubMed     Abstract available


  82. LEE SU, Li CF, Mortales CL, Pawling J, et al
    Increasing cell permeability of N-acetylglucosamine via 6-acetylation enhances capacity to suppress T-helper 1 (TH1)/TH17 responses and autoimmunity.
    PLoS One. 2019;14:e0214253.
    PubMed     Abstract available


  83. TEMPLETON N, Kivell B, McCaughey-Chapman A, Connor B, et al
    Clozapine administration enhanced functional recovery after cuprizone demyelination.
    PLoS One. 2019;14:e0216113.
    PubMed     Abstract available


  84. LANDTBLOM AM, Guala D, Martin C, Olsson-Hau S, et al
    RebiQoL: A randomized trial of telemedicine patient support program for health-related quality of life and adherence in people with MS treated with Rebif.
    PLoS One. 2019;14:e0218453.
    PubMed     Abstract available


  85. GAJAMANGE S, Shelton A, Clough M, White O, et al
    Functional correlates of cognitive dysfunction in clinically isolated syndromes.
    PLoS One. 2019;14:e0219590.
    PubMed     Abstract available


  86. KAPICA-TOPCZEWSKA K, Tarasiuk J, Collin F, Brola W, et al
    The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population.
    PLoS One. 2019;14:e0223863.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: